Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8669431 | 0.91 | KMT2A (0.47) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL11305374 | 0.91 | KMT2A (0.47) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL14826510 | 0.88 | MME (0.45) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL6053670 | 0.88 | CA2 (0.55) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL7046871 | 0.87 | KMT2A (0.44) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL14193621 | 0.86 | BMP1 (0.44) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL8192831 | 0.85 | KMT2A (0.43) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL8192827 | 0.85 | KMT2A (0.43) | KMT2ACA1CA2FOLH1MME | |
| SCHEMBL1177032 | 0.84 | MME (0.58) | KMT2ACA1CA2MME | |
| SCHEMBL1177029 | 0.84 | MME (0.58) | KMT2ACA1CA2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | claimed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | claimed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | claimed |
| EP-2225272-B1 | PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS AS (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| EP-1765861-B1 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS AS (DK) | 2012-02-15 | — | — | EP | disclosed |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | COPENHAGEN UNIVERSITY | 2011-04-28 | — | — | US | disclosed |
| EP-2225272-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | Enkam Pharmaceuticals A/S (DK) | 2010-09-08 | — | — | EP | disclosed |
| EP-1660539-B1 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009068042-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
| US-20090105149-A1 | Compounds comprising lpa | ENKAM PHARMACEUTICALS A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| WO-2005014623-A9 | COMPOUNDS COMPRISING LPA | — | 2006-03-23 | — | — | WO | disclosed |
| WO-2005123759-A2 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005121168-A2 | HEPARIN BINDING PEPTIDE | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005014623-A2 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105149-A1 | Compounds comprising lpa | FGFR1, FGFR3, FGFR2 | KMT2A 2819/4885CA1 3676/4885CA2 2421/4885 |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | L1CAM, FGFR1, FGFR3 | KMT2A 3741/4885CA1 2550/4885CA2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.